Niacin revisited: clinical observations on an important but underutilized drug.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  American Journal of Medicine

• Publication date

  1991-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0002-9343(91)90122-EPMID 1892143
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.

  2009cited by this paper
• Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin.

  1991cited by this paper
• The effect of the American Heart Association step one diet on hyperlipidemia following renal transplantation.

  1990cited by this paper
• Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

  1990cited by this paper
• Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin.

  1990cited by this paper
• Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus.

  1990cited by this paper
• Increased β-Cell Secretory Capacity as Mechanism for Islet Adaptation to Nicotinic Acid-Induced Insulin Resistance

  1989cited by this paper
• Hyperlipidemia after organ transplantation.

  1989cited by this paper
• Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance.

  1989cited by this paper
• Hyperlipidemia after organ transplantation.

  1989cited by this paper
• Nicotinic acid-associated myopathy: a report of three cases.

  1989cited by this paper
• Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.

  1989cited by this paper
• Atherosclerosis in diabetes: the role of hyperinsulinemia.

  1988cited by this paper
• Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.

  1988cited by this paper
• Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.

  1988cited by this paper
• Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.

  1988cited by this paper
• Nicotinic acid-induced fulminant hepatic failure.

  1987cited by this paper
• [8] Single vertical spin density gradient ultracentrifugation

  1986cited by this paper
• Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

  1986cited by this paper
• Single vertical spin density gradient ultracentrifugation.

  1986cited by this paper
• Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin.

  1985cited by this paper
• Niacin hepatitis.

  1983cited by this paper
• Clofibrate and niacin in coronary heart disease.

  1975cited by this paper
• Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustained-action preparations and report of two cases of jaundice.

  1961cited by this paper

• Vitamin metabolism and requirements in chronic kidney disease and kidney failure

  2022cites this paper
• Drug Induced Diabetes

  2021cites this paper
• Type 2 Diabetes: Geriatric Considerations

  2016cites this paper
• Drug-Induced Hyperglycemia and Diabetes Mellitus

  2016cites this paper
• Preconcentration and determination of ceftazidime in real samples using dispersive liquid-liquid microextraction and high-performance liquid chromatography with the aid of experimental design.

  2016cites this paper
• Riociguat: A Novel New Drug for Treatment of Pulmonary Hypertension

  2015cites this paper
• Medication Management of Cardiac Allograft Vasculopathy After Heart Transplantation

  2015cites this paper
• Pathogenesis of Type 2 Diabetes Mellitus

  2015cites this paper
• Second line options for hyperlipidemia management after cardiac transplantation.

  2013cites this paper
• Vitamin Metabolism and Requirements in Renal Disease and Renal Failure

  2013cites this paper
• DRUG - INDUCED DIABETES

  2012cites this paper
• Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice.

  2012cites this paper
• Safety and tolerability of extended-release niacin with laropiprant

  2012cites this paper
• Niacin—A Critical Component to the Management of Atherosclerosis: Contemporary Management of Dyslipidemia to Prevent, Reduce, or Reverse Atherosclerotic Cardiovascular Disease

  2012cites this paper
• A case for immediate-release niacin.

  2012cites this paper
• Statin intolerance: now a solved problem.

  2011cites this paper
• A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.

  2010cites this paper
• CHAPTER 5 – Alternative Systems

  2009cites this paper
• Drug Therapy for Hypercholesterolemia and Dyslipidemia

  2008cites this paper
• Pilot study of combined therapy with ω-3 fatty acids and niacin in atherogenic dyslipidemia.

  2007cites this paper
• Toxicity from the use of niacin to beat urine drug screening.

  2007cites this paper
• Safety considerations with niacin therapy.

  2007cites this paper
• Evaluation of Efficacy and Safety of Fixed Dose Lovastatin and NiacinER Combination in Asian Indian Dyslipidemic Patients: A Multicentric Study

  2006cites this paper
• Cholesterol profile measurement by vertical auto profile method.

  2006cites this paper
• Pharmacotherapy of Hyperlipidemia in Pediatric Heart Transplant Recipients

  2005cites this paper
• Final report of the safety assessment of niacinamide and niacin.

  2005cites this paper
• Clinical Update on the Use of Niacin for the Treatment of Dyslipidemia

  2004cites this paper
• Treatment of hyperlipidemia in cardiac transplant recipients.

  2004cites this paper
• Extended-release niacin for modifying the lipoprotein profile

  2004cites this paper
• Hepatotoxicity of hypolipidemic drugs.

  2003cites this paper
• Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia

  2003cites this paper
• Targeting Cardiovascular Risk Associated with Both Low Density and High Density Lipoproteins Using Statin–niacin Combination Therapy

  2002cites this paper
• [Indications for the pharmacologic treatment of hyperlipidemias].

  2000cites this paper
• Indicaciones del tratamiento farmacológico en las hiperlipidemias

  2000cites this paper
• Treatment of hyperlipidemia in women.

  2000cites this paper
• Effects of niacin therapy that simulate neoplasia: hepatic steatosis with concurrent hepatic dysfunction.

  1999cites this paper
• Ultrasonographic findings in niacin‐induced hepatitis.

  1999cites this paper
• Treatment of hyperlipidemia with combined niacin-statin regimens.

  1998cites this paper
• The effect of garlic on hypercholesterolemia in renal transplant patients.

  1998cites this paper
• Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.

  1998cites this paper
• Pharmacokinetics: The Effect of the Mode of Administration on the Hypolipidaemic Activity of Niacin: Continuous Gastrointestinal Administration of Low‐dose Niacin Improves Lipid‐lowering Efficacy in Experimentally‐induced Hyperlipidaemic Rats

  1998cites this paper
• Dental and gingival pain as side effects of niacin therapy.

  1998cites this paper
• Combination of Low-Dose Niacin and Pravastatin Improves the Lipid Profile in Diabetic Patients without Compromising Glycemic Control

  1997cites this paper
• Pathophysiology and treatment of lipid perturbation after cardiac transplantation.

  1997cites this paper
• Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum.

  1997cites this paper
• Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice.

  1996cites this paper
• Diätetische Maßnahmen und Lipidsenkung

  1996cites this paper
• Combination Therapy with Low‐Dose Lovastatin and Niacin Is as Effective as Higher‐Dose Lovastatin

  1996cites this paper
• Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry.

  1996cites this paper
• Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia.

  1996cites this paper
• Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia.

  1995cites this paper
• Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial.

  1995cites this paper
• Hepatotoxicity of anticholesterol, cardiovascular, and endocrine drugs and hormonal agents.

  1995cites this paper
• Approaches to The Treatment of Hyperlipidemia in the Solid Organ Transplant Recipient

  1995cites this paper
• Update on the treatment of hypercholesterolemia, with a focus on hmg‐coa reductase inhibitors and combination regimens

  1995cites this paper
• A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).

  1995cites this paper
• Dyslipidemias in Patients With Diabetes Mellitus: Classification and Risks and Benefits of Therapy

  1995cites this paper
• Hyperlipidemia: perspectives in diagnosis and treatment.

  1995cites this paper
• A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.

  1994cites this paper
• Criteria for use of hypolipidemic agents in adults.

  1994cites this paper
• Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias.

  1994cites this paper
• Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.

  1994cites this paper
• Principles and Treatment of Lipoprotein Disorders

  1994cites this paper
• Complementary Effects of Pravastatin and Nicotinic Acid in the Treatment of Combined Hyperlipidaemia in Diabetic and Non-Diabetic Patients

  1994cites this paper
• Niacin: a therapeutic dilemma. "One man's drink is another's poison".

  1994cites this paper
• Fluvastatin with and without niacin for hypercholesterolemia.

  1994cites this paper
• Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia.

  1994cites this paper
• The pharmacology of fluvastatin, a new HMG‐CoA reductase inhibitor

  1994cites this paper
• Telephone Contacts Do Not Improve Adherence to Niacin or Bile Acid Sequestrant Therapy

  1994cites this paper
• Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans

  1994cites this paper
• Nicotinic Acid and Derivatives

  1994cites this paper
• Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia.

  1994cites this paper
• Drug treatment of dyslipoproteinemia.

  1994cites this paper
• Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: preliminary experience.

  1993cites this paper
• Transient focal hepatic defects related to sustained-release niacin.

  1993cites this paper
• Drug-Induced Disorders of Glucose Tolerance

  1993cites this paper
• Niacin treatment of hypercholesterolemia in children.

  1993cites this paper
• Risk factors for cardiovascular disease after renal transplantation.

  1993cites this paper
• Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans.

  1993cites this paper
• Variability of lipid measurements: relevance for the clinician.

  1993cites this paper
• Low high-density lipoprotein cholesterol: what does it mean, what can we do about it, and what should we do about it?

  1993cites this paper
• Variabilityof LipidMeasurements: Relevanceforthe Clinician

  1993cites this paper
• The anti-proliferative effects of nicotinamide and 3-aminobenzamide on human smooth muscle cells in vitro.

  1993cites this paper
• Hepatotoxicity associated with sustained-release niacin.

  1992cites this paper
• Detection and Management of Lipid Disorders in Diabetic Patients: A commentary for clinicians

  1992cites this paper
• A survey of resuscitation training in Canadian undergraduate medical programs.

  1992cites this paper
• Familial combined hyperlipoproteinemia.

  1992cites this paper